Cytokine therapy in rheumatoid arthritis.
Hermann
J
J
Mathilda and Kennedy Institute of Rheumatology, Hammersmith, London, UK.
Walmsley
M
M
Brennan
F M
FM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000918:Antibody Specificity; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D016207:Cytokines / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016753:Interleukin-10 / Q000502:physiology / Q000627:therapeutic use; D017370:Interleukin-11 / Q000276:immunology / Q000627:therapeutic use; D015847:Interleukin-4 / Q000502:physiology / Q000627:therapeutic use; D051379:Mice; D011994:Recombinant Proteins / Q000627:therapeutic use; D013582:Synovial Fluid / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000502:physiology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007155:Immunologic Factors; D017370:Interleukin-11; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D015847:Interleukin-4